Success Metrics

Active Trials
1(50%)

Phase Distribution

Ph phase_3
1
50%
Ph not_applicable
1
50%

Phase Distribution

0

Early Stage

0

Mid Stage

1

Late Stage

Phase Distribution2 total trials
Phase 3Large-scale testing
1(50.0%)
N/ANon-phased studies
1(50.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

1

trials recruiting

Total Trials

2

all time

Status Distribution
Active(2)

Detailed Status

Active, not recruiting1
Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials
2
Active
1
Success Rate
N/A
Most Advanced
Phase 3

Trials by Phase

Phase 31 (50.0%)
N/A1 (50.0%)

Trials by Status

active_not_recruiting150%
not_yet_recruiting150%

Recent Activity

1 active trials
Showing 2 of 2
active_not_recruitingphase_3

A Study to Evaluate the Efficacy and Safety of Serplulimab in Combination With Chemotherapy and Concurrent Radiotherapy in Patients With Limited-Stage Small Cell Lung Cancer

NCT05353257
not_yet_recruitingnot_applicable

A Multi-cohort Study of Efbemalenograstim Alfa Injection for Preventing ANC Reduction in Solid Tumor Patients Post Immune-chemotherapy.

NCT06649448

Clinical Trials (2)

Showing 2 of 2 trials
NCT05353257Phase 3

A Study to Evaluate the Efficacy and Safety of Serplulimab in Combination With Chemotherapy and Concurrent Radiotherapy in Patients With Limited-Stage Small Cell Lung Cancer

Active Not Recruiting
NCT06649448Not Applicable

A Multi-cohort Study of Efbemalenograstim Alfa Injection for Preventing ANC Reduction in Solid Tumor Patients Post Immune-chemotherapy.

Not Yet Recruiting

All 2 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
2